Development of Therapeutic Antibodies for Stroke

The excellent therapeutic results achieved with immunotherapy in cancer, autoimmune diseases, and neurodegenerative disorders have attracted many scholars in the field of stroke. Many antibodies have been developed to treat stroke and have demonstrated good therapeutic efficacy in animal models, but clinical trials of some antibodies have ended in failure. Therefore, Ace Therapeutics has improved the existing techniques and processes for the development of antibodies for stroke, providing a more comprehensive and advanced service for the development of therapeutic antibodies for stroke.

Therapeutic Antibody Screening

Current studies have confirmed that many targets for stroke therapy can be used to develop therapeutic antibodies, such as Nogo A, Nogo-66, MAG, Omgp, and others. For more potential targets, we have established several antibody screening technology platforms to rapidly screen for therapeutic antibodies that can be used to treat stroke using proven technologies.

• Hybridoma technology to prepare monoclonal antibodies
  Monoclonal antibodies prepared by hybridoma technology possess both antibody-secreting function and cell immortality.

• Phage display screening technology
  With our unique phage display technology platform, we have prepared libraries of natural antibodies of all human, murine, rabbit, and other primate species in various forms.
• Yeast surface display technology
  We have built a mature yeast display technology platform for high affinity antibody sorting, antigen / antibody library construction, and affinity maturation.

In addition, we also provide ribosome display and mRNA display screening technology, nano-antibody screening technology, transgenic mouse whole human antibody screening technology, and other related services.

Humanized Antibodies

Human anti-mouse antibodies have been found to cause increased infection rates leading to poor prognosis and even death, therefore, antibody humanization modification services are critical. Ace Therapeutics has extensive experience and proven technology in antibody humanization. We perform the humanization of antibodies through DNA recombination and protein engineering technologies, including chimeric antibodies, CDR transplant antibodies, surface remodeling antibodies, and fully human antibodies, to achieve the majority or total elimination of the immunogenicity of heterologous antibodies in humans while retaining antibody specificity.

Preclinical Evaluation of Drug Candidates for the Treatment of Stroke

After obtaining the therapeutic antibodies, we first characterize their potency, specificity, and affinity, and then evaluate the antibodies to assess their therapeutic effect on stroke.

• We perform antibody potency identification by test tube agglutination reaction, agar diffusion assay, and enzyme-linked immunosorbent assay.
• The ability of antibodies to specifically recognize and bind antigens is identified by western blotting, immunohistochemistry, immunocytochemistry, and protein microarrays.
• We ensure the specificity of the antibodies by establishing knockout cell lines and knockout mouse models. In vitro and in vivo stroke models are also established to assess the therapeutic effect of antibodies on stroke.
• The therapeutic effect of antibodies on stroke is assessed by measurement of brain infarct volume, immunohistochemistry, behavioral tests, and other assays.

We offer custom therapeutic antibody development services for the treatment of stroke based on your experimental needs. If you would like to learn more about our services, please feel free to contact us.

1. Yu, C.Y., et al. Therapeutic antibodies in stroke. Transl Stroke Res. 2013, 4(5): p.477-83.